China Shineway Pharmaceutical Group Limited (2877.HK)
- Previous Close
7.360 - Open
7.420 - Bid 7.320 x --
- Ask 7.310 x --
- Day's Range
7.290 - 7.420 - 52 Week Range
7.140 - 10.760 - Volume
979,000 - Avg. Volume
1,353,123 - Market Cap (intraday)
5.514B - Beta (5Y Monthly) 0.77
- PE Ratio (TTM)
6.13 - EPS (TTM)
1.190 - Earnings Date Mar 28, 2025
- Forward Dividend & Yield 0.51 (6.92%)
- Ex-Dividend Date Apr 30, 2025
- 1y Target Est
11.47
China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese pharmaceutical products in the People's Republic of China and Hong Kong. The company offers Chinese medicines in the form of injection, soft capsules, and granules; tablets, pills, oral liquid, and powder; and traditional Chinese medicine granules in various therapeutic areas, including respiratory system disease, nervous system, digestive system disease, cardiovascular and cerebrovascular, orthopedics, pediatrics, and other areas, as well as medication for strengthening the body. It is also involved in the trading of agricultural products. The company was incorporated in 2002 and is headquartered in Shijiazhuang, China. China Shineway Pharmaceutical Group Limited operates as a subsidiary of BH Corporate Services Ltd.
www.shineway.com3,220
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 2877.HK
View MorePerformance Overview: 2877.HK
Trailing total returns as of 5/8/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2877.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2877.HK
View MoreValuation Measures
Market Cap
5.51B
Enterprise Value
-1.08B
Trailing P/E
6.12
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.36
Price/Book (mrq)
0.69
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
22.24%
Return on Assets (ttm)
5.33%
Return on Equity (ttm)
11.59%
Revenue (ttm)
3.78B
Net Income Avi to Common (ttm)
840.05M
Diluted EPS (ttm)
1.190
Balance Sheet and Cash Flow
Total Cash (mrq)
6.49B
Total Debt/Equity (mrq)
4.64%
Levered Free Cash Flow (ttm)
564.33M